Remote biophysical profile, contraceptive patch efficacy explained, FQHC prenatal care gaps

Thank you for visiting the Contemporary OB/GYN website. Take a look at some of our top stories from the past week (Monday, August 3, to Friday, August 7, 2026) and click on each link to read and watch anything you may have missed.

Alex Peahl, MD, MSc, on the feasibility of patient-operated remote biophysical profiles

A University of Michigan pilot study, discussed by lead researcher Alex F. Peahl, MD, MSc, found patient-operated remote ultrasonography feasible for completing biophysical profiles (BPPs) in high-risk pregnancies, a tool that has until now required a clinician physically operating the ultrasound.

Click here to watch.

Jeffrey Jensen, MD, contextualizes contraceptive efficacy in modern trials

The Pearl Index reported for the newly FDA-approved norelgestromin and ethinyl estradiol transdermal system (Gwyn Lo; Viatris) reflects a shift in how contraceptive efficacy is measured in modern US trials rather than a signal clinicians should find concerning, according to Jeffrey Jensen, MD, MPH, Professor, Obstetrics & Gynecology, Oregon Health & Science University.

Click here to watch the full discussion with Jeffrey Jensen, MD.

One in 3 community health centers lack on-site prenatal care, national study finds

About two-thirds of federally qualified health centers (FQHCs) offer on-site prenatal care, while 1 in 3 do not, according to a national study from researchers at the Harvard Pilgrim Health Care Institute and the Boston University School of Public Health, with geographic gaps concentrated in maternity desert regions.

Click here for the full article.

Michael Reed, MD, MSCP, on steps physicians can take to advance women's sexual health

Physicians can begin addressing women's sexual health immediately without becoming subspecialists, according to Michael A. Reed, MD, MSCP, board-certified obstetrician-gynecologist in Davis, California, and a NAMS-certified menopause practitioner, who outlined practical steps building on his proposed "Fourth Pillar" framework for women's health.

Click here to watch the full discussion with Michael Reed, MD, MSCP.

FDA clears Revi Extend implant for urgency urinary incontinence

The FDA granted 510(k) clearance to Revi Extend, an updated implantable tibial neuromodulation system (Revi System; BlueWind Medical, Ltd) for the treatment of urgency urinary incontinence, featuring an extended device life span of 15 years and supported by 3-year data from the pivotal OASIS trial (NCT03596671).

Click here for full study details.